The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents
Abstract
BACKGROUND: Internal documents from the pharmaceutical industry provide a unique window for understanding the structure and methods of pharmaceutical promotion. Such documents have become available through litigation concerning the promotion of gabapentin (Neurontin, Pfizer, Inc., New York, New York) for off-label uses. PURPOSE: To describe how gabapentin was promoted, focusing on the use of medical education, research, and publication. DATA SOURCES: Court documents available to the public from United States ex. rel David Franklin vs. Pfizer, Inc., and Parke-Davis, Division of Warner-Lambert Company, mostly from 1994-1998. DATA EXTRACTION: All documents were reviewed by 1 author, with selected review by coauthors. Marketing strategies and tactics were identified by using an iterative process of review, discussion, and re-review of selected documents. DATA SYNTHESIS: The promotion of gabapentin was a comprehensive and multifaceted process. Advisory boards, consultants meetings, and accredited continuing medical education events organized by third-party vendors were used to deliver promotional messages. These tactics were augmented by the recruitment of local champions and engagement of thought leaders, who could be used to communicate favorable messages about gabapentin to their physician colleagues. Research and scholarship were also used for marketing by encouraging "key customers" to participate in research, using a large study to advance promotional themes and build market share, paying medical communication companies to develop and publish articles about gabapentin for the medical literature, and planning to suppress unfavorable study results. LIMITATIONS: Most available documents were submitted by the plaintiff and may not represent a complete picture of marketing practices. CONCLUSION: Activities traditionally considered independent of promotional intent, including continuing medical education and research, were extensively used to promote gabapentin. New strategies are needed to ensure a clear separation between scientific and commercial activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Qualitative research in health care: Analysing qualitative data
Pope, C. (2000) · BMJ · doi:10.1136/bmj.320.7227.114 · Cited by 8,131
The Influence of Source Credibility on Communication Effectiveness
Hovland, C. I., & Weiss, W. (1951) · Public Opinion Quarterly · doi:10.1086/266350 · Cited by 3,543
The truth about the drug companies: how they deceive us and what to do about it
(2005) · Choice Reviews Online · doi:10.5860/choice.42-5297 · Cited by 885
Brennan, T. A., Rothman, D. J., Blank, L., Blumenthal, D., Chimonas, S. C., Cohen, J. J., Goldman, J., Kassirer, J. P., Kimball, H., Naughton, J., et al. (2006) · JAMA · doi:10.1001/jama.295.4.429 · Cited by 695
Gabapentin in bipolar disorder: a placebo‐controlled trial of adjunctive therapy1
Pande, A. C., Crockatt, J. G., Janney, C. A., Werth, J. L., Tsaroucha, G., & Gabapentin Bipolar Disorder Study Group (2000) · Bipolar Disorders · doi:10.1034/j.1399-5618.2000.20305.x · Cited by 313
Science in the private interest: has the lure of profits corrupted biomedical research?
Krimsky, S. (2006) · IEEE Technology and Society Magazine · doi:10.1109/mtas.2006.1607717 · Cited by 306
A Mechanistic Approach to Antiepileptic Drug Interactions
Anderson, G. D. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.17332 · Cited by 246
The 70% Majority: Enduring Consumer Beliefs about Advertising
Calfee, J. E., & Ringold, D. J. (1994) · Journal of Public Policy & Marketing · doi:10.1177/074391569401300204 · Cited by 223
GORSON, K. C., SCHOTT, C., HERMAN, R., ROPPER, A. H., & RAND, W. M. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.251 · Cited by 206
A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures
Chadwick, D. W., Anhut, H., Greiner, M. J., Alexander, J., Murray, G. H., Garofalo, E. A., Pierce, M. W., & The International Gabapentin Monotherapy Study Group 945-77 (1998) · Neurology · doi:10.1212/wnl.51.5.1282 · Cited by 205
Research works printed but not linked: 7
- 10.1001/jama.289.18.2418 · doi:10.1001/jama.289.18.2418
- 10.1056/NEJMp048322 · doi:10.1056/nejmp048322
- Pollack MH, 1997, CNS Spectrums, 55
- 10.1097/00007611-199907000-00001 · doi:10.1097/00007611-199907000-00001
- Gidal B, 1998, Consultant Pharmacist, 1, 62
- 10.18553/jmcp.1999.5.4.351 · doi:10.18553/jmcp.1999.5.4.351
- 1997, Fed Regist, 62, 64093
Cited by
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
Self-citationDissemination and publication of research findings: an updated review of related biases
Song, F., Parekh, Hooper, L., Loke, Y., Ryder, J., Sutton, A., Hing, C., Kwok, C., Pang, C., & Harvey, I. (2010) · Health Technology Assessment · doi:10.3310/hta14080 · Cited by 1,039
Industry sponsorship and research outcome
Lundh, A., Sismondo, S., Lexchin, J., Busuioc, O. A., & Bero, L. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub2 · Cited by 605
Self-citationGagnon, M.-A., & Lexchin, J. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050001 · Cited by 502
Reporting bias in medical research - a narrative review
McGauran, N., Wieseler, B., Kreis, J., Schüler, Y.-B., Kölsch, H., & Kaiser, T. (2010) · Trials · doi:10.1186/1745-6215-11-37 · Cited by 452
Metadata
- Authors
- Steinman, M. A., Bero, L. A., Chren, M.-M., & Landefeld, C. S.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2006-08-15
- Volume
- 145
- Issue
- 4
- Pages
- 284-293
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2162739163
- Cited by
- 336
- References
- 20
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents. https://app.cochat.ai/papers/10.7326/0003-4819-145-4-200608150-00008
- The paper
- Steinman, M. A., Bero, L. A., Chren, M.-M., & Landefeld, C. S. (2006). Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-145-4-200608150-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.